Japan’s Hemp Cannabinoid Market Soars, Surpassing ¥24 Billion

Major Japanese companies have rapidly launched CBD-infused products, with industry analysts predicting a diverse expansion into various consumer categories, reflecting growing trust and potential in Japan's burgeoning cannabis market.

Google News
Japan's Hemp Cannabinoid Market Soars, Surpassing ¥24 Billion

In a recent report by Euromonitor International, it has been revealed that from 2019 to 2023, Japan’s hemp cannabinoid market has experienced a remarkable expansion, growing sixfold to reach a valuation of ¥24 billion. This surge reflects a growing acceptance and integration of hemp-derived products within the Japanese market.

Legislative changes supporting market growth

December witnessed a historic amendment in Japan as the government revised the Cannabis Control Law. This pivotal change decriminalized the use of cannabis-derived medical products, opening new doors for research and commercialization in this segment. It signifies a progressive shift in governmental policy towards recognizing the medicinal benefits of cannabis derivatives.

The role of major corporations

Major Japanese companies, including UHA Mikakuto and Cheerio, have quickly responded to these legislative updates by launching CBD-infused products such as gummies and drinks. The initiative taken by these large firms hints at the potential scope and trust in the burgeoning cannabis market.

Product types and consumer preferences

The most common type of cannabis-derived product available in Japan is CBD-infused liquids. However, industry analysts like Aya Suzuki from Euromonitor predict a diversified future. Suzuki projects an increase in variety, with large companies venturing into food, beverages, and dietary supplements. This suggests that the market will not only expand in size but also in terms of product offerings, catering to broader consumer needs and preferences.

Challenges in sourcing and customs

Despite significant growth and opportunities, businesses face logistical hurdles, particularly regarding the importation of raw materials. Suzuki pointed out that it is typical for Japanese companies to source ingredients globally; however, there are complexities during the customs process. Many businesses have seen their imports discarded by customs officials due to suspicions or confirmations of THC content, which remains a controlled substance in Japan despite recent law amendments.

Looking forward

The entry of established companies into the market, coupled with broadening product lines and ongoing legal transformations, suggests a robust future for Japan’s cannabinoid industry. Nonetheless, the challenges highlighted around ingredient sourcing and regulatory compliance underscore the need for a systematic approach to ensure continued growth without setbacks.

Japan’s journey in integrating CBD and hemp into its market is emblematic of a broader global trend where countries are gradually modulating their stance on cannabis use based on economic incentives and medical research. As Japan continues to navigate the myriad challenges and possibilities, the rest of the world watches and learns from its approach to policy, business involvement, and customer interaction in the thriving field of cannabinoids.

Rita Ferreira

Rita Ferreira

Rita is a seasoned writer with over five years of experience, having worked with globally renowned platforms, including Forbes and Miister CBD. Her deep knowledge of hemp-related businesses and passion for delivering accurate and concise information distinguish her in the industry. Rita's contributions empower individuals and companies to navigate the complexities of the cannabis world, and her work remains a valuable resource for those seeking a deeper understanding of its potential.

We will be happy to hear your thoughts

      Leave a reply


      The Marijuana Index
      The Marijuana Index
      Logo